Louisiana is currently home to 923 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including New Orleans, Baton Rouge, Shreveport and Metairie. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
Safety and Immunogenicity of an Intranasal Vaccine for Respiratory Syncytial Virus in Seronegative Children 6-36 Months
NCT04909021
Recruiting
This study evaluates an investigational vaccine that is designed to protect humans against infection with respiratory syncytial virus (RSV) and is administered as a nasal spray. Specifically, the study analyzes the safety of, and the immune response to, the vaccine when administered to healthy children between the ages of 6 and 24 months who are seronegative to RSV.
Gender:
All
Ages:
Between 6 months and 36 months
Trial Updated:
08/01/2022
Locations: MedPharmics, Metairie, Louisiana
Conditions: Respiratory Syncytial Virus (RSV)
Register for Updates
A Study to Monitor Ambulatory Blood Pressure Monitoring in Hypogonadal Men Treated With Nasal Testosterone Gel
NCT04976595
Recruiting
The purpose of this study is to assess the change in 24-hour ambulatory blood pressure monitoring (ABPM) between baseline (Day 0) and Day 120 following 4 months of testosterone therapy with Natesto.
Gender:
Male
Ages:
Between 18 years and 80 years
Trial Updated:
07/04/2022
Locations: Tandem Clinical Research GI, LLC, Marrero, Louisiana
Conditions: Hypogonadism
Register for Updates
Safety and Efficacy of the CGuard™ Carotid Stent System in Carotid Artery Stenting
NCT04900844
Recruiting
The objective of this pivotal study is to evaluate the safety and efficacy of the CGuard™ Carotid Stent System in the treatment of carotid artery stenosis in symptomatic and asymptomatic patients undergoing carotid artery stenting (CAS) to a performance goal developed from published CAS literature.
Gender:
All
Ages:
Between 19 years and 80 years
Trial Updated:
06/16/2022
Locations: Oschner Health, New Orleans, Louisiana
Conditions: Carotid Artery Stenosis
Register for Updates
Effect of Different Ingestion Doses of Celastrol on Human Sperm Motility
NCT05413226
Recruiting
Five healthy participants with normal sperm counts and motility will ingest increasing doses of celastrol over a period of several days. After each dose ingestion the participants will provide an ejaculate the next day for sperm analysis. The objective is to see if increasing ingestion levels of celastrol will affect the sperm counts and motility of the participants.
Gender:
Male
Ages:
Between 18 years and 40 years
Trial Updated:
06/07/2022
Locations: Patient Urgent Care Clinic, Baton Rouge, Louisiana
Conditions: Safety Issues
Register for Updates
Field Evaluation of Two Topically Applied Insect Repellent Products Containing IR3535 Against Mosquitos in Louisiana
NCT05394597
Recruiting
To determine the efficacy and duration of protection of two topically applied insect repellent products at preventing landing by mosquitos. The study will follow the EPA Product Performance Test Guidelines1. It is intended to test the products against natural populations of mosquito species of public health importance within the genera Aedes, Anopheles, and Culex, and to replace data from one site previously tested in Florida with data from a site in Louisiana with adequate landing pressure from... Read More
Gender:
All
Ages:
Between 18 years and 55 years
Trial Updated:
05/23/2022
Locations: Louisiana State University, Department of Entomology, Baton Rouge, Louisiana
Conditions: Bites and Stings
Register for Updates
Study to Evaluate Effects of INL1 in Patients With Heart Failure and Reduced Ejection Fraction
NCT03875183
Recruiting
This is a multicenter, randomized, double-blind, placebo-controlled, dose-response trial in patients with chronic stable Heart Failure (HF) and reduced Left Ventricular Ejection Fraction (LVEF) to evaluate the efficacy and safety of three INL1 doses compared with placebo. Patients will be treated for approximately 12 weeks with one of three INL1 doses: 50 mg, 150 mg, 300 mg, or, placebo capsules, taken twice daily (BID).
Gender:
All
Ages:
Between 18 years and 75 years
Trial Updated:
03/28/2022
Locations: Clinical Trials of America LA, LLC, Monroe, Louisiana
Conditions: Heart Failure, Reduced Ejection Fraction
Register for Updates
Next Generation Sequencing Versus Traditional Cultures for Clinically Infected Penile Implants: Impact of Culture Identification on Outcomes
NCT05287438
Recruiting
Randomized prospective study to evaluate next generation sequencing (NGS) and standard-of-care culture for clinically infected penile implants and to compare outcomes with identification of microbes.
Gender:
Male
Ages:
Between 18 years and 80 years
Trial Updated:
03/10/2022
Locations: WK Advanced Urology, Bossier City, Louisiana
Conditions: Penile Implantation, Infections
Register for Updates
Interbody Systems: Post Market Clinical Follow-up Study
NCT04911257
Recruiting
This is a prospective, multi-center study of subjects who will undergo spinal fusion surgery utilizing Stryker Interbody Systems that require post market clinical follow up (PMCF). The primary study hypothesis for each system is that the mean change in NDI (cervical) or ODI (lumbar) from baseline to Month 12 < -10, that is, the mean improvement exceeds 10 points. In supporting analysis, the same hypotheses will be tested for mean change from baseline to 24 months to demonstrate durability of ef... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
03/09/2022
Locations: Spine Institute of Louisiana Foundation, Inc., Shreveport, Louisiana
Conditions: Degenerative Disc Disease
Register for Updates
Prospective Global Registry for the Study of Chronic Total Occlusion Intervention
NCT02061436
Recruiting
Percutaneous coronary intervention (PCI) of chronic total occlusions (CTOs) is increasingly being performed in patients with advanced coronary artery disease, but there is limited information on the techniques utilized and the procedural outcomes. The goal of this multicenter, investigator initiated registry is to collect information on treatment strategies and outcomes of consecutive patients undergoing CTO PCI among various participating centers. The information collected will be used to deter... Read More
Gender:
All
Ages:
All
Trial Updated:
03/08/2022
Locations: Tulane University Heart and Vascular Institute, New Orleans, Louisiana
Conditions: Coronary Artery Disease
Register for Updates
A Tissue Collection Study in Patients Who Respond to Immune Checkpoint Inhibitors to Identify Targets of Tumor-Reactive T Cells.
NCT05230186
Recruiting
T Cell Receptor-engineered T-cell therapy (TCR T-cell therapy) offers a potentially transformative approach to treating cancer, but is currently limited by the lack of known targets (Maus and June, 2016; Ping et al., 2018). Arguably the most clinically meaningful way to discover new targets and TCRs for TCR T-cell therapy is to study the tumor-infiltrating lymphocytes of patients that are actively responding to immune checkpoint inhibitor (ICI) therapy. These T cells are clonally expanded as a r... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
01/27/2022
Locations: Ochsner Clinic Foundation, New Orleans, Louisiana
Conditions: Solid Tumor, Adult
Register for Updates
Study of Acalabrutinib (ACP-196) in Combination With Venetoclax (ABT-199), With and Without Obinutuzumab (GA101) Versus Chemoimmunotherapy for Previously Untreated CLL
NCT05211856
Recruiting
The purpose of this study is to evaluate the efficacy and safety of acalabrutinib in combination with venetoclax and acalabrutinib in combination with venetoclax with and without obinutuzumab compared to chemoimmunotherapy in subjects with previously untreated CLL.
Gender:
All
Ages:
Between 18 years and 130 years
Trial Updated:
01/14/2022
Locations: Research Site, New Orleans, Louisiana
Conditions: Chronic Lymphocytic Leukemia
Register for Updates
Outpatient Liquid Aspirin (OLA)
NCT04937088
Recruiting
The purpose of this study is to obtain reliable and interpretable data to inform future trials regarding our hypothesis that a novel, liquid aspirin formulation can mitigate COVID -19 associated coagulopathy (CAC) . The potential impact is to reduce COVID-19 related hospitalization within 30 days of diagnosis due to (1) pulmonary events including respiratory failure; (2) cardiac events including myocardial infarction and myocarditis (3) venous or arterial thrombotic events; (4) acute renal insuf... Read More
Gender:
All
Ages:
40 years and above
Trial Updated:
12/13/2021
Locations: Lsuhsc-No, New Orleans, Louisiana
Conditions: Covid19
Register for Updates